4D Molecular Therapeutics Raises $90 Million In Series B Financing

California-based gene therapy firm, 4D Molecular Therapeutics (4DMT) has raised $90 million in a Series B financing round, as it takes its lead program to clinical trial in 2019. The company focuses on therapies for adeno-associated viruses (AAV). Funds from the financing advance clinically testing 4DMT’s gene therapies. Its proprietary Therapeutic

Read More